Earnings Call Summary | Harvard Bioscience(HBIO.US) Q2 2024 Earnings Conference
Earnings Call Summary | Harvard Bioscience(HBIO.US) Q2 2024 Earnings Conference
The following is a summary of the Harvard Bioscience, Inc. (HBIO) Q2 2024 Earnings Call Transcript:
以下是哈佛生物科学公司(HBIO)2024年Q2业绩会简报:
Financial Performance:
金融业绩:
Harvard Bioscience reported Q2 2024 revenue of $23.1 million, down $5.7 million from the previous year.
Gross margin for Q2 2024 was 57.2%, slightly lower than last year's 58% due to lower absorption of fixed manufacturing costs.
Operating profit on an adjusted basis was $800,000 or 3.5% of revenue, with adjusted EBITDA at $1.3 million or 5.5% of revenue.
Cash flow from operations for the first half of 2024 was $0.6 million, significantly lower compared to $5.4 million in the same period last year.
哈佛生物科学报告2024年Q2营业收入为2310万美元,较去年同期下降570万美元。
2024年Q2毛利率为57.2%,略低于去年的58%,因固定制造成本吸收量下降。
调整后的营业利润为80万美元,占营业收入的3.5%,调整后的EBITDA为130万美元,占营业收入的5.5%。
2024年上半年经营活动产生的现金流为60万美元,较去年同期的540万美元显著降低。
Business Progress:
业务进展:
The company indicated a shift towards product innovation with new telemetry devices and neurobehavioral monitoring systems expected to boost revenues.
Commercial introduction of new products in electroporation and bioproduction projects, along with a CGMP-compliant amino acid analysis system for bioprocessing applications.
Installation of MEA Organoid platforms for in-vitro data acquisition, particularly in neuro and cardiac toxicology applications, setting up a full production launch in Q1 2025.
公司表示将转向产品创新,新增遥测设备和神经行为监测系统预计将提振收入。
推出新电穿孔和生产项目产品,以及符合CGMP的氨基酸分析系统用于生物加工应用。
安装MEA器官样板平台进行体外数据获取,尤其是在神经和心脏毒理学应用方面,将于2025年Q1开展全面生产发行。
Opportunities:
机会:
New product launches and innovations set to contribute to revenue streams and underpin long-term double-digit growth.
Increased quoting and funnel activity in China and Asia Pacific signals potential revenue stabilization and growth from academic sectors.
新产品的推出和创新有望为收入流提供支撑,并支持长期两位数的增长。
中国和亚洲太平洋地区的增加的报价活动和漏斗活动预示着学术领域的潜在收入稳定和增长。
Risks:
风险:
Continued challenges from lower capital spending by CROs and pharma in the US and Europe affecting preclinical product shipments.
Economic factors including interest rates and energy costs additionally constrain spending in Europe.
美国和欧洲CRO和制药公司资本支出的下降对临床前产品出货构成持续挑战。
利率期货和能源成本等经济因素也限制了欧洲的支出。
More details: Harvard Bioscience IR
更多详细信息:哈佛生物科学IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由AI生成。文章内容的准确性无法完全保证。有关更全面的详细信息,请参阅IR网站。本文只是为投资者提供参考,没有任何指导或推荐建议。